Literature DB >> 22664222

Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program.

María Hortal1, Miguel Estevan, Hilda Laurani, Inés Iraola, Miguel Meny.   

Abstract

INTRODUCTION: Streptococcus pneumoniae pneumonia burden in children was poorly defined in Uruguay. A three-year population-based surveillance demonstrated the impact of the pneumonia in hospitalized children of less than five years of age. To control these diseases in March 2008, Uruguayan health authorities decided to incorporate PCV7 to the National Immunization Program administered at 2, 4 and 12 months of age (2+1 schedule).
OBJECTIVE: To compare the incidence of consolidated pneumonia hospitalization in children less than five years of age before and after pneumococcal conjugate vaccine implementation.
METHODS: Same methodology of the prevaccination study was employed. The surveillance was carried out at the same four hospitals covering a population of 229,128 inhabitants (2004 Census) of whom 10.2% were under five years of age. Clinical data, vaccination status and digitization of their chest X-rays were recorded. A pediatric radiologist blinded to the clinical diagnosis interpreted the digital images according WHO definitions. Bacterial etiology was investigated in blood and/or in pleural fluid.
RESULTS: Between January 1st 2009 and June 30th 2011 patients were enrolled. Out of 23,445 children<5 years of age, 1224 were hospitalized with pneumonia (430 consolidated pneumonias and 794 non consolidated pneumonias). Pleural effusion was recorded in 89 patients. In 48 consolidated pneumonias S. pneumoniae etiology was recognized. Post vaccination incidence rate of consolidated pneumonia in patients aged 12-23 months showed a significant reduction (44.9%) if we compare it with the incidence of pneumonia hospitalization in the previous study. In March 2010, PCV13 replaced PCV7. Compliance of PCV7/13 globally was 92% but the vaccination status varied among the surveyed patients because two catch-ups were carried out in addition to the routine cohort vaccination. From 2009 1st semester to 2011 1st semester incidence rates decline reached 59%.
CONCLUSION: To date, the ongoing surveillance documented a significant decline on incidence of hospitalizations for consolidated pneumonia in children younger than 24 months of age, confirming the success of the 2+1 vaccination schedule.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664222     DOI: 10.1016/j.vaccine.2012.05.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.

Authors:  Jaime E Ordóñez; John Jairo Orozco
Journal:  Cost Eff Resour Alloc       Date:  2015-04-10

2.  All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.

Authors:  Anders Berglund; Mats Ekelund; Mark A Fletcher; Lars Nyman
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

3.  Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay.

Authors:  María Hortal; Miguel Estevan; Miguel Meny; Inés Iraola; Hilda Laurani
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

4.  Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.

Authors:  Gabriela García Gabarrot; Mariana López Vega; Gabriel Pérez Giffoni; Silvia Hernández; Pablo Cardinal; Viviana Félix; Jean Marc Gabastou; Teresa Camou
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

5.  Methods and challenges for the health impact assessment of vaccination programs in Latin America.

Authors:  Ana Marli Christovam Sartori; Andréia de Fátima Nascimento; Tânia Yuka Yuba; Patrícia Coelho de Soárez; Hillegonda Maria Dutilh Novaes
Journal:  Rev Saude Publica       Date:  2016-01-15       Impact factor: 2.106

6.  Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a "3+0" schedule.

Authors:  Sylvia Becker-Dreps; Bryan Blette; Rafaela Briceño; Jorge Alemán; Michael G Hudgens; Gilberto Moreno; Ana Ordoñez; Julio Rocha; David J Weber; Erick Amaya
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

7.  PCV13 vaccination impact: A multicenter study of pneumonia in 10 pediatric hospitals in Argentina.

Authors:  Angela Gentile; Julia Bakir; Verónica Firpo; Enrique V Casanueva; Gabriela Ensinck; Santiago Lopez Papucci; María F Lución; Hector Abate; Aldo Cancellara; Fabiana Molina; Andrea Gajo Gane; Alfredo M Caruso; Alejandro Santillán Iturres; Sofía Fossati
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

8.  Challenges to estimating vaccine impact using hospitalization data.

Authors:  Cynthia Schuck-Paim; Robert J Taylor; Lone Simonsen; Roger Lustig; Esra Kürüm; Christian A W Bruhn; Daniel M Weinberger
Journal:  Vaccine       Date:  2016-11-26       Impact factor: 3.641

9.  Community acquired pneumonia incidence among children less than 5 years of age in Concordia, Argentina: vaccination impact.

Authors:  Raúl O Ruvinsky; Analía Rearte; Judit Kupervaser; Fernando Gentile; Adriana Haidar; Maria E Cafure; Maria Elisa Tito; Federico Avaro; Cristina Cortiana; Hugo Cozzani; Omar Véliz; Sofia Fossati; Mabel Regueira; Carla Vizzotti
Journal:  Rev Panam Salud Publica       Date:  2018-11-09

10.  Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.

Authors:  N Takeuchi; S Naito; M Ohkusu; K Abe; K Shizuno; Y Takahashi; Y Omata; T Nakazawa; K Takeshita; H Hishiki; T Hoshino; Y Sato; N Ishiwada
Journal:  Epidemiol Infect       Date:  2020-04-17       Impact factor: 2.451

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.